These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11857003)

  • 1. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.
    Ries S; Korn WM
    Br J Cancer; 2002 Jan; 86(1):5-11. PubMed ID: 11857003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-selective viruses for cancer therapy.
    Biederer C; Ries S; Brandts CH; McCormick F
    J Mol Med (Berl); 2002 Mar; 80(3):163-75. PubMed ID: 11894142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.
    Kirn D
    Expert Opin Biol Ther; 2001 May; 1(3):525-38. PubMed ID: 11727523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in adenovirus-mediated p53 cancer gene therapy.
    Tazawa H; Kagawa S; Fujiwara T
    Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oncolytic potency of replicative adenovirus expressing p53.
    Nemunaitis J; Cunningham C; Senzer N
    Drug Resist Updat; 2003 Feb; 6(1):5-7. PubMed ID: 12654282
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
    Wold WS; Toth K
    Curr Gene Ther; 2013 Dec; 13(6):421-33. PubMed ID: 24279313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concepts in Oncolytic Adenovirus Therapy.
    Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic biotherapy: a novel therapeutic plafform.
    Hawkins LK; Lemoine NR; Kirn D
    Lancet Oncol; 2002 Jan; 3(1):17-26. PubMed ID: 11905600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C; Lemmon M; Kirn D
    Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replicative oncolytic adenoviruses in multimodal cancer regimens.
    Post DE; Khuri FR; Simons JW; Van Meir EG
    Hum Gene Ther; 2003 Jul; 14(10):933-46. PubMed ID: 12869212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.
    Sauthoff H; Pipiya T; Heitner S; Chen S; Norman RG; Rom WN; Hay JG
    Hum Gene Ther; 2002 Oct; 13(15):1859-71. PubMed ID: 12396618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells.
    Cherubini G; Petouchoff T; Grossi M; Piersanti S; Cundari E; Saggio I
    Cell Cycle; 2006 Oct; 5(19):2244-52. PubMed ID: 16969092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn D
    Gene Ther; 2001 Jan; 8(2):89-98. PubMed ID: 11313778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
    Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smarter viruses. Onyx pharmaceuticals, Inc.
    Wells WA
    Chem Biol; 2000 Dec; 7(12):R223-4. PubMed ID: 11137823
    [No Abstract]   [Full Text] [Related]  

  • 17. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus.
    Zurakowski R; Wodarz D
    J Theor Biol; 2007 Mar; 245(1):1-8. PubMed ID: 17095020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity.
    Garofalo M; Iovine B; Kuryk L; Capasso C; Hirvinen M; Vitale A; Yliperttula M; Bevilacqua MA; Cerullo V
    Mol Cancer Ther; 2016 Apr; 15(4):651-60. PubMed ID: 26861248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
    Nemunaitis J; Cunningham C; Tong A; Post L; Netto G; Paulson AS; Rich D; Blackburn A; Sands B; Gibson B; Randlev B; Freeman S
    Cancer Gene Ther; 2003 May; 10(5):341-52. PubMed ID: 12719704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.